---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-036543"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:49:03.639316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

## Summary
- Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.
- Board authorized up to $1 billion in share repurchases through March 31, 2026.
- Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.
- Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.
- Net income of $309.5 million, or $6.86 per basic share, up 11%.

## SEC filing metadata
- accession: 0001628280-25-036543
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/0001628280-25-036543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/uthr-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-036543
- JSON: https://secwatch.observer/filing/0001628280-25-036543.json
- Plain text: https://secwatch.observer/filing/0001628280-25-036543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.